Efficacy in Alzheimer's disease
An efficacious treatment for moderate to severe Alzheimer’s disease
- A meta analysis from six Phase III, placebo-controlled, 6-months studies showed that there was a statistically significant effect in favour of Ebixa (memantine) treatment for the cognitive, global, and functional domains.
- The analysis included 1,826 patients with moderate to severe Alzheimer's disease (MMSE <20) (ref.1).
Significant effect of Ebixa in preventing marked clinical worsening in moderate to severe Alzheimer's disease (ref.2) ***p<0.001 |
-
Prevention of clinical worsening is a relevant and realistic treatment goal in Alzheimer’s disease. Ebixa has shown a statistical significant effect in preventing concurrent clinical worsening in all three domains; cognitive, global and functional domains. Twice as many placebo treated patients showed worsening in all three domains compared to Ebixa (mematine) (Placebo 21% vs. memantine 11%, p<0.0001)
-
The analysis included 1,826 patients with moderate to severe Alzheimer’s disease (MMSE < 20)
References:
1. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in Moderate to Severe Alzheimer's Disease: a Meta-Analysis of Randomised Clinical Trials. Dement Geriatr Cogn Disord 2007; 24(1):20-27.
2. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24(2):138-145.